酵素誘導性ナノ繊維集合体によるがん治療のための標的PROTAC放出
Yuchen Yang1,2, Chunrong Yang1, Zongliang Fu3
1New Cornerstone Science Laboratory, Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing, China.
Advanced healthcare materials
|February 24, 2026
まとめ
本研究では、がん治療強化のための新規ペプチド複合体を導入する。新しいPROTACデリバリーシステムは、腫瘍ターゲティングと薬剤効力を改善し、標的タンパク質分解のための有望な戦略を提供する。
関連する概念動画
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Site-Targeted Drug Delivery Systems: Polymeric Carriers
57
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
57
Modified-Release Drug Delivery Systems: Site-Targeted
45
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
45


